Changes in the treatment landscape of metastatic hormone‐sensitive prostate cancer following approval of upfront androgen receptor signaling inhibitors: A multicenter study

Documenti analoghi

• Real‐World Comparative Study of Apalutamide Versus Bicalutamide in Combination With Androgen Deprivation Therapy for Metastatic Hormone‐Sensitive Prostate Cancer
  di: Hidetsugu Takahashi, et al.
  Pubblicazione: (2026)
• Comparison of abiraterone, enzalutamide, and apalutamide for metastatic hormone‐sensitive prostate cancer: A multicenter study
  di: Takafumi Yanagisawa, et al.
  Pubblicazione: (2024)
• Assessment of Circulating Neuroendocrine Tumor Markers at Prostate Cancer Diagnosis: An Investigation of Prostate Cancer With Neuroendocrine Features
  di: Tatsuya Shimomura, et al.
  Pubblicazione: (2026)
• Intermittent Arterial Hemorrhage From Ureteral‐Arterial Fistula After Long‐Term Ureteral Stenting
  di: Kentaro Yoshihara, et al.
  Pubblicazione: (2026)
• Clinical features of medication‐related osteonecrosis of the jaw in prostate cancer management
  di: Yuma Goto, et al.
  Pubblicazione: (2025)